BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 7964482)

  • 1. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1.
    Peach RJ; Bajorath J; Brady W; Leytze G; Greene J; Naemura J; Linsley PS
    J Exp Med; 1994 Dec; 180(6):2049-58. PubMed ID: 7964482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28.
    Peach RJ; Bajorath J; Naemura J; Leytze G; Greene J; Aruffo A; Linsley PS
    J Biol Chem; 1995 Sep; 270(36):21181-7. PubMed ID: 7545666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential recognition by CD28 of its cognate counter receptors CD80 (B7.1) and B70 (B7.2): analysis by site directed mutagenesis.
    Truneh A; Reddy M; Ryan P; Lyn SD; Eichman C; Couez D; Hurle MR; Sekaly RP; Olive D; Sweet R
    Mol Immunol; 1996 Feb; 33(3):321-34. PubMed ID: 8649453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of conserved amino acids in murine B7-1IgV domain critical for CTLA4/CD28:B7 interaction by site-directed mutagenesis: a novel structural model of the binding site.
    Guo Y; Wu Y; Kong X; Liu Y
    Mol Immunol; 1998 Mar; 35(4):215-25. PubMed ID: 9736337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CTLA-4 is a second receptor for the B cell activation antigen B7.
    Linsley PS; Brady W; Urnes M; Grosmaire LS; Damle NK; Ledbetter JA
    J Exp Med; 1991 Sep; 174(3):561-9. PubMed ID: 1714933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational analysis and an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain.
    Guo Y; Wu Y; Zhao M; Kong XP; Liu Y
    J Exp Med; 1995 Apr; 181(4):1345-55. PubMed ID: 7535334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.
    Linsley PS; Greene JL; Tan P; Bradshaw J; Ledbetter JA; Anasetti C; Damle NK
    J Exp Med; 1992 Dec; 176(6):1595-604. PubMed ID: 1334116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.
    Linsley PS; Greene JL; Brady W; Bajorath J; Ledbetter JA; Peach R
    Immunity; 1994 Dec; 1(9):793-801. PubMed ID: 7534620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular cloning and expression of feline CD28 and CTLA-4 cDNA.
    Choi IS; Hash SM; Collisson EW
    Vet Immunol Immunopathol; 2000 Aug; 76(1-2):45-59. PubMed ID: 10973685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cytoplasmic domain of CD28 is both necessary and sufficient for costimulation of interleukin-2 secretion and association with phosphatidylinositol 3'-kinase.
    Stein PH; Fraser JD; Weiss A
    Mol Cell Biol; 1994 May; 14(5):3392-402. PubMed ID: 8164687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure of murine CTLA-4 and its role in modulating T cell responsiveness.
    Ostrov DA; Shi W; Schwartz JC; Almo SC; Nathenson SG
    Science; 2000 Oct; 290(5492):816-9. PubMed ID: 11052947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the site of interaction of CD28 with its counter-receptors CD80 and CD86 and correlation with function.
    Kariv I; Truneh A; Sweet RW
    J Immunol; 1996 Jul; 157(1):29-38. PubMed ID: 8683128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4). A disulfide-linked homodimer binds two CD86 molecules.
    Linsley PS; Nadler SG; Bajorath J; Peach R; Leung HT; Rogers J; Bradshaw J; Stebbins M; Leytze G; Brady W
    J Biol Chem; 1995 Jun; 270(25):15417-24. PubMed ID: 7541042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion.
    Rennert P; Furlong K; Jellis C; Greenfield E; Freeman GJ; Ueda Y; Levine B; June CH; Gray GS
    Int Immunol; 1997 Jun; 9(6):805-13. PubMed ID: 9199963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2).
    Morton PA; Fu XT; Stewart JA; Giacoletto KS; White SL; Leysath CE; Evans RJ; Shieh JJ; Karr RW
    J Immunol; 1996 Feb; 156(3):1047-54. PubMed ID: 8557978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interaction properties of costimulatory molecules revisited.
    Collins AV; Brodie DW; Gilbert RJ; Iaboni A; Manso-Sancho R; Walse B; Stuart DI; van der Merwe PA; Davis SJ
    Immunity; 2002 Aug; 17(2):201-10. PubMed ID: 12196291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions.
    Greene JL; Leytze GM; Emswiler J; Peach R; Bajorath J; Cosand W; Linsley PS
    J Biol Chem; 1996 Oct; 271(43):26762-71. PubMed ID: 8900156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion.
    Wu Y; Guo Y; Huang A; Zheng P; Liu Y
    J Exp Med; 1997 Apr; 185(7):1327-35. PubMed ID: 9104819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for an additional ligand, distinct from B7, for the CTLA-4 receptor.
    Razi-Wolf Z; Galvin F; Gray G; Reiser H
    Proc Natl Acad Sci U S A; 1993 Dec; 90(23):11182-6. PubMed ID: 7504299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cattle CTLA-4, CD28 and chicken CD28 bind CD86: MYPPPY is not conserved in cattle CD28.
    Parsons KR; Young JR; Collins BA; Howard CJ
    Immunogenetics; 1996; 43(6):388-91. PubMed ID: 8606060
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.